LONDON--(BUSINESS WIRE)--According to the latest market study released by Technavio, the global factor VIII deficiency treatment market is projected to grow to USD 11 billion, at a CAGR of close to 6% over the forecast period.
This research report titled ‘Global Factor VIII Deficiency Treatment Market 2017-2021’ provides an in-depth analysis of the market in terms of revenue and emerging market trends. This market research report also includes up to date analysis and forecasts for various market segments and all geographical regions.
The Americas is projected to generate the highest revenue and maximum incremental growth in the global factor VIII deficiency treatment market over the forecast period. The high quality of the healthcare sector catering to the requirements of a large number of hemophilia patients in the region is responsible for the growth of the regional segment.
Request a sample report: http://www.technavio.com/request-a-sample?report=57068
Technavio’s sample reports are free of charge and contain multiple sections of the report including the market size and forecast, drivers, challenges, trends, and more.
Based on disease management, the report categorizes the global factor VIII deficiency treatment market into the following segments:
- Prophylaxis
- On-demand therapy
- Inhibitor therapy
Prophylaxis
“Prophylaxis is the largest segment of the factor VIII deficiency treatment market, generating over 52% of the overall revenue. The treatment involves the steady infusion of clotting factors in patients to maintain their levels at 1% or higher at all times,” says Sapna Jha, a lead analyst at Technavio for infectious and rare diseases research.
Physicians consider factors such as age, venous access, the status of joints, and bleeding symptoms to design this treatment approach. Prophylactic treatment is highly preferred by both patients and healthcare professionals as it is very cost-effective. It is applied based on either the Malmo protocol or the Utrecht protocol.
On-demand therapy
On-demand therapy accounts for nearly 28% of the global factor VIII deficiency treatment market. This treatment route is suitable when bleeding needs to be arrested as soon as it begins and prevents its spread to joints and muscles. The slow acting on-demand hemophilia therapeutics for disease management finds significant market opportunities in emerging economies, where market penetration is increasing steadily. Desmopressin is one of the important drugs prescribed for on-demand therapeutics for the immediate control of bleeding in factor VIII deficiency.
Inhibitor therapy
Inhibitors are antibodies that are developed in hemophilia A patients with factor VIII, which is recognized as a foreign substance. They are developed in the body following the treatment for hemophilia A in nearly 30% of the patients.
“Inhibitor therapies involves a combination of high-dose clotting factor concentrate, bypassing agent, and immune tolerance induction therapies. This market segment currently occupies 20% of the global market share, with the highest growth expected from emerging economies,” says Sapna.
The top vendors highlighted by Technavio’s research analysts in this report are:
- Bayer Healthcare
- CSL
- Grifols
- Novo Nordisk
- Pfizer
- Shire
Browse Related Reports:
- Global Hemophilia Drugs Market 2016-2020
- Global Blood Coagulation Analyzer Market 2016-2020
- Global Alpha-1 Antitrypsin Drugs Market 2016-2020
Become a Technavio Insights member and access all three of these reports for a fraction of their original cost. As a Technavio Insights member, you will have immediate access to new reports as they’re published in addition to all 6,000+ existing reports covering segments like cardiovascular devices, central nervous system, and in-vitro diagnostics. This subscription nets you thousands in savings, while staying connected to Technavio’s constant transforming research library, helping you make informed business decisions more efficiently.
About Technavio
Technavio is a leading global technology research and advisory company. The company develops over 2000 pieces of research every year, covering more than 500 technologies across 80 countries. Technavio has about 300 analysts globally who specialize in customized consulting and business research assignments across the latest leading edge technologies.
Technavio analysts employ primary as well as secondary research techniques to ascertain the size and vendor landscape in a range of markets. Analysts obtain information using a combination of bottom-up and top-down approaches, besides using in-house market modeling tools and proprietary databases. They corroborate this data with the data obtained from various market participants and stakeholders across the value chain, including vendors, service providers, distributors, resellers, and end-users.
If you are interested in more information, please contact our media team at media@technavio.com.
